drugset / Trial / NCT02172339

The Pharmacokinetic, Safety and Tolerability of Tiotropium in Outpatients With Renal Impairment in Comparison to Healthy Subjects

NCT02172339

Phase 1 Completed 24 enrolled Boehringer Ingelheim
Parallel-groupOpen-labelTreatment

Summary

Study to investigate pharmacokinetics of a single i.v. dose of tiotropium (4.8 mcg) in patients with renal impairment in comparison to healthy subjects.

Timeline

Start
1998-04
Primary completion
1998-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Tiotropium Other / unclassified 4.8 ug Intravenous